Letter to Islet Sciences, Inc. (ISLT) Shareholders From CEO James Green

Letter to Islet Sciences, Inc. (ISLT) Shareholders From CEO James Green 
RALEIGH, NC -- (Marketwired) -- 12/12/13 --  Islet Sciences, Inc.
(OTCBB: ISLT) (OTCQB: ISLT) 
Dear Islet Shareholder, 
It is with great pleasure that I begin to communicate with our
shareholders about the future of Islet Sciences, Inc. (OTCBB: ISLT)
(OTCQB: ISLT) (the "Company" or "Islet"). Dr. Wilkison, Islet's COO,
and I have been working together for several years at both
GlaxoSmithKline and BHV Pharma, and are now excited to have joined
the team at Islet. While our vision is long term, expectations for
near-term success are high. In recent months, our Company has faced
significant challenges. But the commitment from your Board to see
Islet through these difficult times has been unwavering. The Board's
efforts on this front are a clear testament to the Company's pipeline
and its potential to positively impact the lives of patients
suffering from diabetes.  
We are committed to building our brand of translating great science
into value by changing the way clinicians and their patients think
about the diagnosis and treatment of metabolic disease. Metabolic
diseases, diabetes in particular, are unfortunately a growth market
with vast unmet needs. On the one hand we still do not fully
understand the mechanism behind the onset of type 1 diabetes where
the result of an autoimmune dysfunction leads to a lifetime of
exogenous insulin dependence. On the other, social and demographic
trends associated with every-day life continue to contribute to the
rapid worldwide growth in incidence rates of type 2 diabetes. The
work that we do is important because the growing population of
diabetic patients is in need of new, more effective, and better
tolerated treatments.  
Our mission is to pursue near-term value generating catalysts while
challenging ourselves to think long-term and develop a sustainable
business model. Our daily efforts will focus on patients and their
doctors, to better understand their needs and deliver to them
actionable commercial solutions in a way that is efficient for
shareholders.  
So you can expect to begin seeing some changes fairly shortly. Not
necessarily in our scientific focus, but in the way we approach the
business of being the best company we can be. We hope to create
shareholder value every day and ultimately position Islet as a
recognized leader in the development of therapeutics and diagnostics
for the treatment and care of patients with metabolic disease. Some
recent changes we have made that are directed at increasing
shareholder value are as follows: 


 
--  In November we conducted the Company's first ever formal portfolio
    review of all development programs. During this process, we enlisted
    the help of an external panel of highly skilled experts in various
    scientific and pharmaceutical fields. This review provided clarity and
    vision for how best to move each program forward while stimulating
    creative ideas for additional opportunities to explore.
--  We are consolidating operations centrally under a
    one-company/one-pipeline strategy as we move away from independently
    managed programs.
--  The Company has begun to address deficiencies in its internal control
    structure by instituting more rigorous controls and hiring another
    member of the finance team in support of our Chief Financial Officer.
--  Important steps have been taken to solidify all of the Company's
    relationships with key partner organizations. This work is ongoing but
    we believe these relationships are strong and mutually committed.
--  We have also initiated business development initiatives aimed at
    partnering for the strategic development of existing programs as well
    as in-licensing additional programs. The Company has ongoing
    negotiations with multiple parties and we are excited about what we
    see on the horizon and what these efforts may eventually mean for
    Islet.
--  Lastly, we have begun the process of transitioning the company's
    headquarters to Research Triangle Park, NC ("RTP"), one of the
    country's top life sciences industry clusters. RTP has an active
    ecosystem of pharmaceutical and biotech companies, including the
    country's greatest concentration of clinical research organizations,
    and is surrounded by three prominent research universities.

  
This transition period will continue to be challenging in the near
term. But with the commitment from your Board and management, and the
support of our partners, I am confident that the Islet of the not so
distant future will look and feel dramatically different from where
we are today. I am excited to be a part of Islet Sciences and am
confident this transition will lead to a bright future for our
Company.  
James Green 
CEO, Islet Sciences, Inc. 
About Islet Sciences 
 Islet Sciences is a biopharmaceutical company
developing novel technologies for the diagnosis and treatment of
patients suffering from metabolic diseases. For more information:
www.isletsciences.com  
Forward-Looking Statements
 This press release contains
forward-looking statements. Forward-looking statements for Islet
Sciences, Inc. reflect current expectations, as of the date of this
press release, and involve certain risks and uncertainties. Actual
results could differ materially from those anticipated in these
forward- looking statements as a result of various factors. Factors
that could cause future results to materially differ from the recent
results or those projected in forward-looking statements include the
risks described in the Islet Science, Inc.'s reports filed with the
Securities and Exchange Commission. The Company's further development
is highly dependent on future medical and research developments and
market acceptance, which is outside of the Company's control. 
Contact:
Investor Relations
Islet Sciences, Inc.
8601 Six Forks Rd, Suite 400
Raleigh, NC 27615
919.480.1518
info@isletsciences.com